Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms.
Cancer
PD-L1
algorithms
immunohistochemistry
immunotherapy
scoring systems
Journal
Current drug targets
ISSN: 1873-5592
Titre abrégé: Curr Drug Targets
Pays: United Arab Emirates
ID NLM: 100960531
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
11
2019
revised:
30
11
2019
accepted:
02
12
2019
pubmed:
24
1
2020
medline:
22
9
2021
entrez:
24
1
2020
Statut:
ppublish
Résumé
The detection of the Programmed Death Ligand 1 (PD-L1) protein by immunohistochemistry is currently the only approved test predictive of response to drugs targeting the PD1/PDL1 axis. The role of this test is debated since several reagents have been used as companion diagnostics for different drugs on diverse immunostaining platforms. In addition, different scoring systems for PD-L1 immunohistochemistry have been applied in the registration studies regarding single drugs. This review deals with the various issues that are related to the immunohistochemical test for PD-L1. We discuss currently unsolved problems such as the advantages and the flaws of PD-L1 immunohistochemistry; the choice of the best reagents and the best scoring system. Finally, we review the current experiences on the role of immunohistochemistry for PD-L1 in clinical trials with immune checkpoint inhibitors.
Identifiants
pubmed: 31971109
pii: CDT-EPUB-103867
doi: 10.2174/1389450121666200123124642
doi:
Substances chimiques
Antibodies, Monoclonal
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1286-1292Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.